In this review article from Future Oncology find out about the PACIFIC trial design as well as the future of immunotherapy combinations and biomarkers beyond PD-L1.
Among prostate cancer patients, those with DNA mismatch repair mutations have particularly aggressive progression and reduced survivability. Though these tumors are more resistant to traditional treatment methods, a recent study has shown that they may be more susceptible to immunotherapy.
The ground breaking CAR-T therapy – Kymriah® – is set to become the first personalized cancer therapy available on the NHS.
Researchers have demonstrated that artificial intelligence can provide a predictive score for the efficacy of immunotherapy in cancer patients.
Cost–effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access
Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation; find out more in this article from Immunotherapy.
A gene that’s associated with an autoimmune form of hair loss could be exploited to improve cancer immunotherapy, suggests a new mouse study.
Checkpoint inhibitors increase median survival to 12.4 months, and more than double percentage of patients who survive 4 years or longer.
Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice
Find out more about the utility of clinical characteristics in the selection of patients with advanced NSCLC as potential candidates for single-agent anti-PD-1/PD-L1 immunotherapy in this open access Future Oncology review article.
The Phase III IMpassion130 study, investigating TECENTRIQ® plus Abraxane® for triple-negative breast cancer, has met its progression-free survival endpoint.
Researchers have uncovered a key mechanism that drives hormone therapy resistance in prostate cancer.